Opens in a new tab

EOFLOW v Insulet (CoA, 18 March 2026)

Date18 March 2026
CourtCoA
DivisionLuxembourg (LU)
Type of actionAppeal RoP220.2
Case number(s)UPC_CoA_930/2025
Registry referenceUPC-COA-0000930/2025
PartiesEOFLOW Co., Ltd. v. Insulet Corporation

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

In an order of 18 March 2026 (UPC_CoA_930/2025), the UPC Court of Appeal dismissed EOFlow Co., Ltd.’s appeal against the Milan Central Division order of 4 December 2025 (UPC_CFI_1167/2025), which had refused to treat as confidential under Rule 262.2 business information disclosed to Insulet Corporation in compliance with an order to provide information (EP 4 201 327). The court held that there is no implicit limitation on the use of information received from the other side: only an order under Rule 262A restricts such use. For a party obliged to disclose sensitive data, the lesson is plain: protection must be sought before disclosure.

Question

Can business information disclosed to the opponent without a protective order still be withheld from the public under Rule 262.2?

Decision

A trade secret requires information that is secret, has commercial value because it is secret and has been subject to reasonable steps to keep it secret (paragraph 18, Article 39(2) TRIPS). Rules 262 and 262A also cover other confidential information (paragraph 23). The court rejected the notion of an implicit procedural restriction: information received without restriction is no longer a trade secret or other confidential information (paragraphs 26 and 27). A Rule 262.2 request does not protect against disclosure to the other party. Only Rule 262A does (paragraph 29), and EOFlow had not sought such an order, having even stated that it was unnecessary (paragraph 30). The assertion about the content of a settlement, already set out in a published order, is public (paragraphs 31 to 33). The appeal was dismissed and EOFlow must bear Insulet’s costs of the appeal.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 24(1)(d), Art. 58 and Art. 69(1)
Rules of Procedure
Rules 262.1(b), 262.2 and 262A
Other provisions
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), Art. 39(2), Directive (EU) 2016/943
Case law cited
Court of Appeal, Strabag v Swarco Futurit, 1 August 2025, UPC_CoA_70/2025, Court of Appeal, Kodak v Fujifilm, 14 October 2025, Court of Appeal, Docket Navigator v Syngenta, 19 December 2025, Court of Appeal, Gowling WLG (Boe v Zentiva Portugal), 24 February 2026, Court of Appeal, Meril v Swat, 5 May 2025, UPC_CoA_634/2024, Court of Appeal, EOFlow v Insulet, 29 January 2026

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CoA_930/2025 official number

Follow this case

First instance cited in the decision: UPC_CFI_1167/2025

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 4 December 2025 Insulet v EOFLOW (CFI, 4 December 2025) Application RoP262A · UPC_CFI_1167/2025

    The Milan Central Division ordered EOFLOW to pay a penalty of EUR 150,000 for violating the preliminary injunction granted by the Court of Appeal on 30 April 2025, on the basis of evidence that EOFLOW had exported 11,520 insulin pump devices to Italy and Sweden between May and July 2025 in breach of that injunction, an…

  2. 29 January 2026 EOFlow v Insulet (CoA, 29 January 2026) Application RoP262.2 · UPC_CoA_930/2025

    Les pièces déposées comme confidentielles sont rendues accessibles à l’autre partie et la demande de restriction d’usage est rejetée : les informations communiquées en exécution d’une injonction ne sont protégées que par une demande au titre de la règle 262A.

  3. 4 February 2026 EOFlow v Insulet (CoA, 4 February 2026) Appeal RoP220.2 · UPC_CoA_930/2025 · appeal, first-instance number cited in the decision

    L’appel contre l’ordonnance prononçant une astreinte et fixant les frais est irrecevable faute d’autorisation expresse de la division de première instance. La demande d’effet suspensif est rejetée.

  4. 18 March 2026 EOFLOW v Insulet (CoA, 18 March 2026) Appeal RoP220.2 · UPC_CoA_930/2025 · appeal, first-instance number cited in the decision

What the record states

Nature of the act
Appeal RoP220.2
Outcome (Dhenne Avocats summary)
La cour d'appel rejette l'appel d'EOFlow : les informations communiquées à Insulet sans ordonnance au titre de la règle 262A ne sont plus des secrets d'affaires ni des informations confidentielles, aucune limitation implicite d'usage n'existant.
Appeal
Decision of the Court of Appeal (first instance cited: UPC_CFI_1167/2025).
Instance
Court of Appeal decision.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) · EOFLOW v Insulet (CFI, 28 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.